Exploring the Frontiers of Psychedelic Medicine: A Deep Dive into COMP360 Psilocybin Treatment for Bipolar II and CYB003 for Major Depressive Disorder

Executed on:Feb 16, 2024 10:30 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Professor and Chairman, Department of Psychiatry at major US academic center.
Treats 100 patients for Major Depressive Disorder and 30 patients with Bipolar II; able to discuss the literature to date on COMP360 Psilocybin Treatment for Bipolar II and CYB003 for Major Depressive Disorder.
Areas of clinical and research interest include thet pathophysiology and treatment of anxiety disorders, developing novel pharmacologic agents for anxiety and mood disorders, and combining the use of cognitive-behavioral and pharmacologic therapies for refractory patients.

Interview Goal

This interview aims to delve into the groundbreaking results from the recent studies on COMP360 psilocybin treatment for treatment-resistant bipolar type II disorder and CYB003 in major depressive disorder. The focus will be on understanding the efficacy, safety, and potential paradigm shift these treatments could bring to the field of psychiatric medicine.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.